IRADIMED Croissance future

Future contrôle des critères 3/6

IRADIMED devrait augmenter ses bénéfices et ses revenus de 15.5% et de 13.9% par an respectivement, tandis que le BPA devrait croître de croître de 14.6% par an.

Informations clés

15.5%

Taux de croissance des bénéfices

14.6%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	17.0%
Taux de croissance des recettes	13.9%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	01 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

Aug 08

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Feb 23

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Feb 05

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

Oct 10

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Aug 23

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Aug 17

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

Jul 29

IRadimed: Reduce Equity Beta With Upside Capture

Jul 18

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Jul 13

At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?

Feb 05

Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital

Jan 12

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:IRMD - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	99	27	N/A	N/A	1
12/31/2025	81	21	N/A	N/A	2
12/31/2024	73	19	N/A	N/A	2
9/30/2024	71	19	17	24	N/A
6/30/2024	69	19	13	16	N/A
3/31/2024	68	18	11	13	N/A
12/31/2023	66	17	5	13	N/A
9/30/2023	63	16	5	13	N/A
6/30/2023	60	15	7	15	N/A
3/31/2023	56	14	5	13	N/A
12/31/2022	53	13	8	10	N/A
9/30/2022	50	13	9	10	N/A
6/30/2022	48	12	9	10	N/A
3/31/2022	45	10	11	12	N/A
12/31/2021	42	9	11	11	N/A
9/30/2021	38	6	10	10	N/A
6/30/2021	35	5	8	8	N/A
3/31/2021	32	1	5	6	N/A
12/31/2020	32	1	5	6	N/A
9/30/2020	34	4	7	7	N/A
6/30/2020	36	5	8	9	N/A
3/31/2020	39	10	10	11	N/A
12/31/2019	39	10	10	10	N/A
9/30/2019	36	8	9	10	N/A
6/30/2019	34	8	7	7	N/A
3/31/2019	32	7	6	6	N/A
12/31/2018	30	6	7	7	N/A
9/30/2018	29	5	5	5	N/A
6/30/2018	27	3	N/A	6	N/A
3/31/2018	25	2	N/A	5	N/A
12/31/2017	23	0	N/A	3	N/A
9/30/2017	22	1	N/A	4	N/A
6/30/2017	24	3	N/A	6	N/A
3/31/2017	29	5	N/A	7	N/A
12/31/2016	32	7	N/A	9	N/A
9/30/2016	35	8	N/A	10	N/A
6/30/2016	35	9	N/A	9	N/A
3/31/2016	33	8	N/A	9	N/A
12/31/2015	31	8	N/A	8	N/A
9/30/2015	26	5	N/A	4	N/A
6/30/2015	22	4	N/A	3	N/A
3/31/2015	19	3	N/A	3	N/A
12/31/2014	15	2	N/A	3	N/A
9/30/2014	15	2	N/A	4	N/A
6/30/2014	14	2	N/A	3	N/A
3/31/2014	12	2	N/A	2	N/A
12/31/2013	11	2	N/A	1	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de IRMD ( 15.5% par an) est supérieure au taux d'épargne ( 2.6% ).

Bénéfices vs marché: Les bénéfices de IRMD ( 15.5% par an) devraient croître plus rapidement que le marché US ( 15.4% par an).

Croissance élevée des bénéfices: Les bénéfices de IRMD devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de IRMD ( 13.9% par an) devrait croître plus rapidement que le marché US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de IRMD ( 13.9% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de IRMD devrait être élevé dans 3 ans

IRADIMED Croissance future

Future contrôle des critères 3/6

Informations clés

Mises à jour récentes de la croissance future

Iradimed Corporation Revises Earnings Guidance for the Year 2024

IRadimed Corporation Provides Revenue Guidance for the First Quarter and Full Year of 2024

Iradimed Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Price target increased by 9.5% to US$57.50

IRadimed Corporation Provides Earnings Guidance for the Third Quarter and for the Full Year of 2023

Price target increased by 14% to US$52.50

Recent updates

Iradimed Corporation Revises Earnings Guidance for the Year 2024

IRADIMED CORPORATION to Report Q3, 2024 Results on Oct 31, 2024

IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

IRADIMED CORPORATION Declares A Regular Quarterly Cash Dividend, Payable on August 30, 2024

IRADIMED CORPORATION to Report Q2, 2024 Results on Aug 01, 2024

Independent Director recently sold US$84k worth of stock

Upcoming dividend of US$0.15 per share

IRADIMED CORPORATION Declares Regular Quarterly Cash Dividend, Payable on May 30, 2024

Now 25% overvalued

IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024

IRADIMED CORPORATION to Report Q1, 2024 Results on May 02, 2024

Now 21% overvalued

Now 21% overvalued after recent price rise

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

IRadimed Corporation Provides Revenue Guidance for the First Quarter and Full Year of 2024

Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

IRadimed Corporation to Report Q4, 2023 Results on Feb 08, 2024

Director notifies of intention to sell stock

IRadimed Corporation Approves Initiation of Regular Quarterly Dividend, Payable on January 12, 2024

Director notifies of intention to sell stock

Independent Director recently sold US$122k worth of stock

Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Iradimed Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

IRadimed Corporation to Report Q3, 2023 Results on Nov 03, 2023

Founder notifies of intention to sell stock

Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

Price target increased by 9.5% to US$57.50

IRadimed Corporation Provides Earnings Guidance for the Third Quarter and for the Full Year of 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

IRadimed Corporation to Report Q2, 2023 Results on Aug 03, 2023

Founder notifies of intention to sell stock

Independent Director recently sold US$128k worth of stock

Price target increased by 14% to US$52.50

IRadimed Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 16%

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Iradimed Corporation Approves Special Cash Dividend, Payable on February 21, 2023

IRadimed Corporation to Report Q4, 2022 Results on Feb 02, 2023

Investor sentiment improves as stock rises 16%

Price target increased to US$46.00

IRadimed Corporation Provides Earnings Guidance for the First Quarter of 2023 and Full Year 2023

Independent Director exercised options to buy US$87k worth of stock.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Iradimed Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

IRadimed Corporation to Report Q3, 2022 Results on Nov 03, 2022

IRadimed Corporation Provides Revenue Guidance for the Third Quarter Ended September 30, 2022

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

IRadimed Corporation Announces Board Changes

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Investor sentiment deteriorated over the past week

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Independent Director recently sold US$116k worth of stock

Insufficient new directors

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

IRadimed Corporation to Report Q2, 2022 Results on Jul 29, 2022

IRadimed: Reduce Equity Beta With Upside Capture

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Insufficient new directors

IRadimed Corporation Names John F. Glenn as Chief Financial Officer, Effective on or before June 20, 2022

Price target decreased to US$40.00

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$53.00